Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rallybio Corporaton (RLYB)

Rallybio Corporaton (RLYB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,719
  • Shares Outstanding, K 5,280
  • Annual Sales, $ 640 K
  • Annual Income, $ -57,780 K
  • EBIT $ -38 M
  • EBITDA $ -40 M
  • 60-Month Beta -1.05
  • Price/Sales 42.08
  • Price/Cash Flow N/A
  • Price/Book 0.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.04
  • Number of Estimates 1
  • High Estimate -1.04
  • Low Estimate -1.04
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +48.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.67 +37.87%
on 02/17/26
5.80 -12.76%
on 01/23/26
+0.14 (+2.85%)
since 01/20/26
3-Month
3.67 +37.87%
on 02/17/26
6.40 -20.94%
on 12/17/25
+0.18 (+3.69%)
since 11/20/25
52-Week
1.76 +187.37%
on 04/08/25
6.63 -23.68%
on 02/21/25
-1.10 (-17.87%)
since 02/20/25

Most Recent Stories

More News
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical...

RLYB : 5.06 (+6.53%)
Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and...

RLYB : 5.06 (+6.53%)
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash...

RLYB : 5.06 (+6.53%)
Rallybio (RLYB) Receives a Hold from Evercore ISI

In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Hold rating on Rallybio, with a price target of $1.00. The company’s shares closed yesterday at $0.56.Elevate Your Investing...

RLYB : 5.06 (+6.53%)
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –    – Data Readouts for Completed...

RLYB : 5.06 (+6.53%)
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia...

RLYB : 5.06 (+6.53%)
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END

AVAI : 0.3994 (+0.55%)
RLYB : 5.06 (+6.53%)
BTAI : 1.5700 (-3.09%)
RXRX : 3.42 (-8.06%)
PFE : 26.65 (-0.78%)
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

– Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest...

RLYB : 5.06 (+6.53%)
Regulatory Green Lights Are Powering the Next Phase of the AI Health Boom

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence is rapidly transforming the healthcare landscape, unlocking new possibilities...

TREIF : 0.4820 (+6.85%)
AVAI : 0.3994 (+0.55%)
RLYB : 5.06 (+6.53%)
SDGR : 11.53 (-3.03%)
RXRX : 3.42 (-8.06%)
ACN : 215.35 (+0.19%)
TRUE.CN : 0.5100 (-1.92%)
Here's Why Shares in Recursion Pharmaceuticals Surged Today

RLYB : 5.06 (+6.53%)
RXRX : 3.42 (-8.06%)

Business Summary

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

See More

Key Turning Points

3rd Resistance Point 6.06
2nd Resistance Point 5.75
1st Resistance Point 5.41
Last Price 5.06
1st Support Level 4.76
2nd Support Level 4.45
3rd Support Level 4.11

See More

52-Week High 6.63
Last Price 5.06
Fibonacci 61.8% 4.77
Fibonacci 50% 4.20
Fibonacci 38.2% 3.62
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar